ABOUT BLENREP

(belantamab mafodotin-blmf)

What is BLENREP?

BLENREP is a prescription medicine used to treat multiple myeloma in adults whose cancer has come back or did not respond to prior treatment and who have already received at least 4 prior therapies, including at least 1 therapy from each of these classes of drugs:

BLENREP is approved based on patient response rate. Studies are ongoing to confirm the clinical benefit of BLENREP for this use.

Doctor discussing how BLENREP works with patient

How BLENREP works

BLENREP is an antibody-drug conjugate (ADC) that targets B-cell maturation antigen (BCMA)

What is BCMA?

BCMA is a protein found on the surface of healthy plasma cells and cancerous myeloma cells alike. BCMA helps fuel cell growth and protects cells from dying.

BCMA is found at higher levels on myeloma cells.

BCMA is a protein found on the surface of myeloma cells

What is an ADC?

An ADC is made of a cell-killing medication attached to an antibody.

BLENREP is an antibody-drug conjugate (ADC) that targets B-cell maturation antigen (BCMA)
BCMA is a protein found on the surface of myeloma cells
BLENREP is an antibody-drug conjugate (ADC) that targets B-cell maturation antigen (BCMA)

BLENREP works in different ways to help your body fight multiple myeloma

BLENREP identifies cells that express BCMA and attaches directly to the BCMA protein.

  • It is possible that healthy immune cells will be affected

BLENREP is brought into the cancerous myeloma cells, releasing medication resulting in cell death.

Meanwhile, the antibody part of the BLENREP ADC attracts the immune system to recognize the cancerous myeloma cells and attack them.

BLENREP attaches directly to the BCMA protein
BLENREP attracts immune cells
top-texture
Top-white-texture

BLENREP works in different ways from other multiple myeloma medications

It is the first and only ADC that targets BCMA, and also uses your body’s own immune system to recognize and attack the cancerous myeloma cells.

It is possible that healthy immune cells will be affected.

bottom-texture
Bottom white texture

How was BLENREP studied?

BLENREP was studied in patients with a broad range of characteristics

The results include the 97 patients who received the recommended dose of BLENREP. Patients received BLENREP as an intravenous infusion once every 3 weeks.

A range of patients with relapsed/refractory multiple myeloma were included in the study

  • 53% were male, with an average age of 65 years
  • Patients had a median of 7 prior treatments across the population
  • Patients who had received at least 3 and up to 21 prior treatments, including at least 1 from each of these classes of drugs:
    • an immunomodulatory agent, like Revlimid (lenalidomide), Pomalyst (pomalidomide), or Thalomid (thalidomide)
    • a proteasome inhibitor, like Velcade (bortezomib), Kyprolis (carfilzomib), or Ninlaro (ixazomib)
    • an anti-CD38 monoclonal antibody, like Darzalex (daratumumab)
  • Patients with high-risk cytogenetics* (27%)
  • Patients who had mild or moderate impaired kidney function (74%), which is a common complication in patients with relapsed/refractory multiple myeloma

*Presence of t(4;14), t(14;16), or 17p13del mutations.

Response with BLENREP was seen in patients whose cancer had returned or progressed multiple times

  • Ninety-seven patients received the recommended single-agent dose of BLENREP. About a quarter of these patients had high-risk cytogenetics
  • Patients in the trial had received at least 3 and up to 21 prior treatment regimens
  • Patients’ responses were observed at 6 months and again at 13 months, to provide information on the longer-term benefits and risks of BLENREP

At 6 months

Response to treatment in approximately

31% of patients

In patients who responded:

Time to response was about

6 weeks

Response lasted at least

6 months in most patients (73%)

BLENREP showed a very good partial response or better in

60% of patients

(18 out of 30 patients)

In the 97 patients evaluated at 6 months, 2 patients (2%) had a stringent complete response, 1 (1%) had a complete response, 15 (15%) had a very good partial response, and 12 (12%) had a partial response.

BLENREP patient

In the 97 patients evaluated at 6 months, 2 patients (2%) had a stringent complete response, 1 (1%) had a complete response, 15 (15%) had a very good partial response, and 12 (12%) had a partial response.

At 13 months

At the 13-month follow-up, approximately 32% of patients had a response to treatment. The response lasted about 11 months.

Learn more about BLENREP Risks & Side Effects

Top-white-texture

I tell others with this disease to try to live life to the fullest.*

– Cynthia, BLENREP patient

Explore stories from Cynthia and other real patients on BLENREP.

*Individual results vary.

SEE PATIENT STORIES